DSM-5 cannabis use disorder: a phenotypic and genomic perspective.
about
Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based reviewGenetic Moderation of Stress Effects on Corticolimbic CircuitryMonoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysisGenome-wide Association Study of Cannabis Dependence Severity, Novel Risk Variants, and Shared Genetic RisksGenetic and Environmental Factors Associated with Cannabis Involvement.Whole genome sequence study of cannabis dependence in two independent cohorts.KAT2B polymorphism identified for drug abuse in African Americans with regulatory links to drug abuse pathways in human prefrontal cortex.An association study revealed substantial effects of dominance, epistasis and substance dependence co-morbidity on alcohol dependence symptom count.Natural outcome of cannabis use disorder: a 3-year longitudinal follow-up.Genetic variation in FAAH is associated with cannabis use disorders in a young adult sample of Mexican Americans.A genome-wide association study of social genetic effects in Landrace pigs.The Cannabis Abuse Screening Test and the DSM-5 in the general population: Optimal thresholds and underlying common structure using multiple factor analysis.Psychotic patients who used cannabis frequently before illness onset have higher genetic predisposition to schizophrenia than those who did not.Genome-wide association study identifies a novel locus for cannabis dependence.Gene variants and educational attainment in cannabis use: mediating role of DNA methylation.Human Genetics of Addiction: New Insights and Future Directions.
P2860
Q26746192-B74A9240-996E-47E6-906A-0C11DAF07B68Q28606435-B28DE1D4-36BB-4D9F-9D63-FCA0D578836EQ36429054-A6E02C34-709C-4842-89DE-3B5B4366192AQ37154235-BFB43739-E7D0-45AE-BC33-38C5CC79980AQ37249137-E0D06A5C-684F-4A69-AF62-4DB7A64CD688Q39006186-54B86D6D-348B-4CE6-B28F-588658706E9EQ40299016-4F0B1705-9536-4BE3-A5B3-AEAFD78FB1DBQ40766616-C00C2357-8622-4357-B923-E25B0C2E8D00Q41546234-FDFED9A5-BC2B-4630-B2CF-649433BAA068Q42211009-CE7256C0-38E2-47FA-9478-2737689105FDQ47265452-627AFF72-4ECA-4070-BD40-958693EBC835Q47575883-8A31710C-1685-475E-83E2-507D39858EF1Q47608789-27D10CE2-C593-4D92-9FDE-FE5D4B4CE6B0Q47641216-009661F9-6B4B-4DC0-A9CA-7FDAD23E0CE6Q49894668-68B47380-B2C9-4C71-BA7D-4F26BF73F5ACQ52316078-D5F17B52-BED9-4149-9B2C-AD94CBA1FEF4
P2860
DSM-5 cannabis use disorder: a phenotypic and genomic perspective.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
DSM-5 cannabis use disorder: a phenotypic and genomic perspective.
@en
DSM-5 cannabis use disorder: a phenotypic and genomic perspective.
@nl
type
label
DSM-5 cannabis use disorder: a phenotypic and genomic perspective.
@en
DSM-5 cannabis use disorder: a phenotypic and genomic perspective.
@nl
prefLabel
DSM-5 cannabis use disorder: a phenotypic and genomic perspective.
@en
DSM-5 cannabis use disorder: a phenotypic and genomic perspective.
@nl
P2093
P2860
P50
P1476
DSM-5 cannabis use disorder: a phenotypic and genomic perspective.
@en
P2093
Eric O Johnson
John R Kramer
Manav Kapoor
P2860
P304
P356
10.1016/J.DRUGALCDEP.2013.11.008
P50
P577
2013-11-16T00:00:00Z